Role of hepatitis D virus infection in development of hepatocellular carcinoma among chronic hepatitis B patients treated with nucleotide/nucleoside analogues

[1]  N. Tan,et al.  Risk Estimation for Infection in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention: Development and Validation of a Predictive Score , 2022, Frontiers in Cardiovascular Medicine.

[2]  Ming‐Lung Yu,et al.  Serial serologic changes of hepatitis D virus in chronic hepatitis B patients receiving nucleos(t)ides analogues therapy , 2020, Journal of gastroenterology and hepatology.

[3]  O. Weiland,et al.  Long‐Term Study of Hepatitis Delta Virus Infection at Secondary Care Centers: The Impact of Viremia on Liver‐Related Outcomes , 2020, Hepatology.

[4]  F. Negro,et al.  Chronic hepatitis D and hepatocellular carcinoma: A systematic review and meta-analysis of observational studies. , 2020, Journal of hepatology.

[5]  Li Liu.  Clinical features of hepatocellular carcinoma with hepatitis B virus among patients on Nucleos(t) ide analog therapy , 2020, Infectious Agents and Cancer.

[6]  G. Papatheodoridis,et al.  New epidemiology of hepatitis delta , 2020, Liver international : official journal of the International Association for the Study of the Liver.

[7]  Rui Huang,et al.  REAL-B (Real-world Effectiveness from the Asia Pacific Rim Liver Consortium for HBV) Risk Score for the Prediction of Hepatocellular Carcinoma in Chronic Hepatitis B Patients Treated with Oral Antiviral Therapy. , 2020, The Journal of infectious diseases.

[8]  Ming‐Lung Yu,et al.  Pharmacokinetics and pharmacodynamics of pegylated interferon for the treatment of hepatitis B , 2019, Expert opinion on drug metabolism & toxicology.

[9]  T. Santantonio,et al.  Clinical outcomes in patients with hepatitis D, cirrhosis and persistent hepatitis B virus replication, and receiving long‐term tenofovir or entecavir , 2019, Alimentary pharmacology & therapeutics.

[10]  F. Negro,et al.  A review on hepatitis D: From virology to new therapies , 2019, Journal of advanced research.

[11]  Sheng-Nan Lu,et al.  Taiwan consensus statement on the management of chronic hepatitis B. , 2019, Journal of the Formosan Medical Association = Taiwan yi zhi.

[12]  Young Don Kim,et al.  Modified PAGE-B score predicts the risk of hepatocellular carcinoma in Asians with chronic hepatitis B on antiviral therapy. , 2018, Journal of hepatology.

[13]  V. Wong,et al.  Development of a scoring system to predict hepatocellular carcinoma in Asians on antivirals for chronic hepatitis B. , 2018, Journal of hepatology.

[14]  U. Haberkorn,et al.  Strategies for the treatment of HBV/HDV , 2018, European journal of pharmacology.

[15]  Ning Zhang,et al.  Anti‐viral therapy is associated with improved survival but is underutilised in patients with hepatitis B virus‐related hepatocellular carcinoma: real‐world east and west experience , 2018, Alimentary pharmacology & therapeutics.

[16]  J. Kao,et al.  Review article: the prevention of hepatitis B‐related hepatocellular carcinoma , 2018, Alimentary pharmacology & therapeutics.

[17]  M. Abecassis,et al.  AASLD guidelines for the treatment of hepatocellular carcinoma , 2018, Hepatology.

[18]  M. Kudo,et al.  Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update , 2017, Hepatology International.

[19]  D. Leslie,et al.  Independent of Cirrhosis, Hepatocellular Carcinoma Risk Is Increased with Diabetes and Metabolic Syndrome. , 2017, The American journal of medicine.

[20]  P. Lampertico,et al.  Hepatitis B virus long‐term impact of antiviral therapy nucleot(s)ide analogues (NUCs) , 2017, Liver international : official journal of the International Association for the Study of the Liver.

[21]  Ming‐Lung Yu,et al.  Hepatitis D virus infections among injecting drug users with and without human immunodeficiency virus infection in Taiwan , 2016, The Kaohsiung journal of medical sciences.

[22]  M. Levrero,et al.  Aiming for cure in HBV and HDV infection. , 2016, Journal of hepatology.

[23]  N. Hiramatsu,et al.  The suppressive effect of nucleos(t)ide analogue treatment on the incidence of hepatocellular carcinoma in chronic hepatitis B patients , 2016, Journal of gastroenterology and hepatology.

[24]  J. Kao,et al.  Perspectives and control of hepatitis B virus infection in Taiwan. , 2015, Journal of the Formosan Medical Association = Taiwan yi zhi.

[25]  Ming‐Lung Yu,et al.  Changing hepatitis D virus epidemiology in a hepatitis B virus endemic area with a national vaccination program , 2015, Hepatology.

[26]  Jaw-Town Lin,et al.  Association of nucleos(t)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B: a nationwide cohort study. , 2014, Gastroenterology.

[27]  S. Alavian,et al.  Prevalence of Hepatitis Delta Virus (HDV) Infection in Chronic Hepatitis B Patients with Unusual Clinical Pictures , 2013, Hepatitis monthly.

[28]  H. El‐Serag,et al.  Epidemiology of viral hepatitis and hepatocellular carcinoma. , 2012, Gastroenterology.

[29]  Vincent Wai-Sun Wong,et al.  Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score. , 2011, The Lancet. Oncology.

[30]  Chien-Jen Chen,et al.  Natural history of chronic hepatitis B REVEALed , 2011, Journal of gastroenterology and hepatology.

[31]  Ming‐Lung Yu,et al.  Viral Hepatitis Infections in Southern Taiwan: A Multicenter Community‐based Study , 2010, The Kaohsiung journal of medical sciences.

[32]  M. Colombo,et al.  A 28-year study of the course of hepatitis Delta infection: a risk factor for cirrhosis and hepatocellular carcinoma. , 2009, Gastroenterology.

[33]  W. Chang,et al.  Performance characteristics of two real-time PCR assays for quantification of hepatitis B virus DNA , 2009, Scandinavian journal of infectious diseases.

[34]  G. Fattovich,et al.  Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. , 2008, Journal of hepatology.

[35]  V. de Lédinghen,et al.  Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. , 2005, Gastroenterology.

[36]  W. Sheng,et al.  Comparison of clinico-pathological features in hepatitis B virus-associated hepatocellular carcinoma with or without hepatitis D virus superinfection. , 1996, Journal of hepatology.

[37]  T. Kurimura,et al.  Risk of liver cirrhosis and hepatocellular carcinoma in subjects with hepatitis B and delta virus infection: A study from Kure, Japan , 1993, Journal of gastroenterology and hepatology.

[38]  C. Chu,et al.  Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. , 2007, Journal of hepatology.